These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30636274)

  • 21. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
    Tanaka M; Kimura T; Iwamura Y; Enei Y; Iwamoto Y; Imai Y; Inaba Y; Matsukawa A; Onuma H; Ito K; Mori K; Sasaki H; Miki J; Furuta A; Miki K; Egawa S
    Prostate; 2019 Oct; 79(14):1604-1610. PubMed ID: 31376184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience].
    Chanal E; Bousarsar A; Vallard A; Méry B; Vincent L; Flechon A; Chanelière AF; Daguenet E; Bouleftour W; Vassal C; Magné N; Guillot A
    Bull Cancer; 2020 Feb; 107(2):171-180. PubMed ID: 31901292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
    Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
    World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2014 Apr; 14():31. PubMed ID: 24742323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
    Mangir N; Türkeri L
    Actas Urol Esp; 2014 Oct; 38(8):515-22. PubMed ID: 24646918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
    Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Man YN; Chen YF
    Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
    Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
    Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.
    He D; Sun Z; Guo J; Zhang Z; Shan Y; Ma L; Li H; Jin J; Huang Y; Xiao J; Wei Q; Ye D
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):144-150. PubMed ID: 30873737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients.
    Kita Y; Shimizu Y; Inoue T; Kamba T; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2013 Aug; 18(4):718-23. PubMed ID: 22791141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.